查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1716441

2032 年糖尿病药物市场预测：按产品、糖尿病类型、形式、分销管道和地区进行的全球分析

Diabetes Drugs Market Forecasts to 2032 - Global Analysis By Product (Insulin, Oral Anti-Diabetic Drugs, Injectable Non-Insulin Drugs and Combination Drugs), Diabetes Type, Formulation, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球糖尿病药物市场预计在 2025 年达到 943 亿美元，到 2032 年将达到 1,736 亿美元，预测期内的复合年增长率为 9.1%。

抗糖尿病药物是用来控製糖尿病患者血糖值的药物。这些药物透过多种机制发挥作用，包括刺激胰岛素分泌、改善胰岛素敏感性、抑制葡萄糖吸收和增加尿糖排泄。这些药物分为不同类别——胰岛素製剂、GLP-1受体促效剂、SGLT2抑制剂和口服降血糖药物——并根据1型或2型糖尿病患者的特定需求量身定制。透过调节血糖浓度，这些药物有助于预防糖尿病相关併发症，如心血管和神经病变。配方的不断进步旨在提高疗效和患者治疗效果。

根据国际糖尿病联盟（IDF）提供的最新数据，2021年，全球20-79岁成年人中有5.37亿人被诊断出患有糖尿病。预计到2030年这数字将达到6.43亿，到2045年将达到7.83亿。

全球糖尿病盛行率上升

都市化加快、久坐不动的生活方式和不健康的饮食习惯是导致第 1 型和第 2 型糖尿病发病率上升的主要原因。诊断工具和早期检测技术的进步对有效治疗的需求更大。此外，包括长效胰岛素製剂和联合治疗在内的药物开发的快速进展正在提高治疗的有效性和便利性。旨在传播糖尿病意识和鼓励定期健康检查的公共卫生措施正在对市场产生积极影响。

糖尿病药物高成本

高级胰岛素製剂和口服抗糖尿病药物价格高昂，限制了人们的负担能力，尤其是在中低收入地区。复杂的製造流程和严格的监管要求推高了生产成本，影响了供应和定价。农村和欠发达地区医疗服务有限，进一步限制了人们获得优质糖尿病管理解决方案的机会。总的来说，这些因素阻碍了尖端糖尿病药物的广泛应用，并限制了市场成长潜力。

个人化医疗和客製化治疗方案日益普及

基因检测和生物标记识别的进步使医疗保健专业人员能够根据患者的个别需求量身定制治疗方法。穿戴式胰岛素帮浦和智慧注射器等药物传输系统的持续技术创新将提高患者的便利性和对治疗方法的依从性。扩大基因疗法和再生医学等替代疗法的研究将开闢新的成长途径。这种对改善健康结果和减少併发症的关注正在推动个人化解决方案的采用。

来自学名药和替代疗法的竞争

广泛使用的药物的低成本学名药的出现影响了品牌药物的市场占有率和收益。非药物干预，例如饮食调整和运动计划，通常可以提供补充解决方案并减少药物依赖。围绕实验性糖尿病治疗及其长期有效性的伦理问题可能会破坏消费者的信任。此外，地缘政治紧张局势和贸易限制可能会扰乱製药生产所用关键成分和原材料的供应链。

COVID-19的影响：

COVID-19 疫情影响了供应链和医疗保健系统，扰乱了糖尿病药物市场。生产延误和物流挑战限制了药品的获取，导致一些地区出现药品短缺。在关闭期间，医院就诊次数减少和常规检查延迟影响了糖尿病的诊断和治疗。然而，这场大流行凸显了糖尿病患者面临严重后果的脆弱性，并促使人们提高对糖尿病管理的认识和重视。

口服糖尿病药物市场预计将在预测期内实现最大幅度增长

口服抗糖尿病药物由于其便利性和广泛使用，预计在预测期内将占据最大的市场占有率。这些药物包括双胍类和 DPP-4 抑制剂，可有效控制血糖，且易于服用，因此深受患者欢迎。配方和联合治疗的进步进一步提高了治疗效果并减少了副作用。糖尿病高发生率地区的采用率不断提高以及宣传宣传活动的加强也促进了该领域的持续成长。

预计生物相似药胰岛素製剂领域在预测期内将以最高复合年增长率成长

由于越来越多地采用具有成本效益的品牌胰岛素製剂替代品，预计生物相似药胰岛素领域将在预测期内实现最高成长率。生物相似药胰岛素具有相当的安全性和有效性，对于希望降低治疗成本的医疗保健提供者来说是一个有吸引力的选择。监管部门的核准和新型生物相似药的进入正在推动该市场的成长。

比最大的地区

由于糖尿病盛行率高且医疗保健投资不断增加，预计亚太地区将在预测期内占据最大的市场占有率。中国、印度和日本等国家由于糖尿病患者数量庞大且医疗服务覆盖范围不断扩大而在该地区占据主导地位。旨在改善糖尿病管理的政府措施和宣传宣传活动进一步推动了市场成长。该地区强大的製药生产能力和对可负担治疗的关注确保了其持续的市场主导。

复合年增长率最高的地区：

在预测期内，由于糖尿病治疗技术和研究的重大进步，预计北美将呈现最高的复合年增长率。主要企业的存在和强大的医疗保健基础设施支持了药物开发的创新。由于生活方式的改变，糖尿病盛行率不断上升，推动了对有效且易于获得的药物的需求。此外，优惠的报销政策和生物相似药胰岛素的日益普及也促进了市场的成长。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章全球糖尿病药物市场（按产品）

  • 胰岛素
    • 速效胰岛素
      • Aspart胰岛素
      • Insulin Lispro
      • Insulin Glulisine
    • 长效胰岛素
      • Insulin Detemir
      • Insulin Degludec
    • 速效胰岛素
      • 优泌林R
      • 诺和灵
    • 中效胰岛素
  • 口服抗糖尿病药物
    • 双胍类
    • 磺酰尿素类
    • 胰岛素增敏剂（TZD）
    • DPP-4抑制剂
    • SGLT-2抑制剂
    • α-Glucosidase酶抑制剂
  • 胰岛素以外的注射药物
    • GLP-1受体促效剂
    • Amylin 类似物
  • 伴随用药

第六章 全球糖尿病药物市场（依糖尿病类型）

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病
  • 糖尿病前期/葡萄糖耐受不良

7. 全球糖尿病药物市场（按形式）

  • 管瓶
  • 笔
  • 泵浦
  • 生物相似药胰岛素
  • 其他形式

8. 全球糖尿病药物市场（依分销管道）

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他分销管道

9. 全球糖尿病药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Abbott
  • Adocia
  • Amgen
  • AstraZeneca
  • Bayers AG
  • Biocon
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co.
  • Mylan
  • Novartis
  • Novo Nordisk
  • Peptron
  • Pfizer
  • Sanofi
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
Product Code: SMRC29252

According to Stratistics MRC, the Global Diabetes Drugs Market is accounted for $94.3 billion in 2025 and is expected to reach $173.6 billion by 2032 growing at a CAGR of 9.1% during the forecast period. Diabetes drugs are medications designed to manage blood sugar levels in individuals with diabetes mellitus. These drugs work through various mechanisms, such as enhancing insulin secretion, improving insulin sensitivity, reducing glucose absorption, or increasing glucose excretion via urine. They are categorized into different classes, including insulin, GLP-1 receptor agonists, SGLT2 inhibitors, and oral hypoglycemic agents, tailored to the specific needs of Type 1 or Type 2 diabetes patients. By regulating glucose levels, these medications help prevent complications associated with diabetes, such as cardiovascular issues and nerve damage. Continuous advancements in drug formulations aim to improve efficacy and patient outcomes.

According to the latest data provided by the International Diabetes Federation (IDF), in 2021, 537 million adults aged 20-79 years were diagnosed with diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Rising prevalence of diabetes globally

Increased urbanization, sedentary lifestyles, and unhealthy eating habits have significantly contributed to the growing incidence of Type 1 and Type 2 diabetes. Advances in diagnostic tools and early detection technologies further raise the demand for effective treatments. Moreover, rapid advancements in drug development, including long-acting insulin formulations and combination therapies, boost treatment efficacy and convenience. Public health initiatives aimed at spreading diabetes awareness and promoting regular health check-ups have positively impacted the market.

Restraint:

High costs associated with diabetes medications

Premium pricing of advanced insulin and oral anti-diabetic drugs limits affordability, especially in low- and middle-income regions. Complex manufacturing processes and strict regulatory requirements add to production expenses, impacting supply and pricing dynamics. Limited availability of healthcare services in rural and underdeveloped areas further restricts access to quality diabetes management solutions. These factors collectively hinder the widespread adoption of cutting-edge diabetes drugs and constrain the market's growth potential.

Opportunity:

Growing popularity of personalized medicine and tailored treatment plans

Advances in genetic testing and biomarker identification enable healthcare professionals to customize therapies based on individual patient needs. Continuous innovation in drug delivery systems, such as wearable insulin pumps and smart injectors, enhances patient convenience and adherence to treatment regimens. Expanding research into alternative treatments, including gene therapy and regenerative medicine, opens new avenues for growth. Thus the focus on improving health outcomes and minimizing complications boosts the adoption of personalized solutions.

Threat:

Competition from generic drugs and alternative therapies

The availability of low-cost generic versions of widely used medications impacts market share and revenue for branded drugs. Non-pharmaceutical interventions, such as dietary adjustments and exercise programs, often provide complementary solutions, reducing dependency on drugs. Ethical concerns surrounding experimental diabetes treatments and their long-term efficacy can undermine consumer confidence. Furthermore geopolitical tensions and trade restrictions may disrupt the supply chain for critical ingredients and raw materials used in drug manufacturing.

Covid-19 Impact:

The COVID-19 pandemic disrupted the diabetes drugs market by affecting supply chains and healthcare delivery systems. Manufacturing delays and logistics challenges limited the availability of medications, creating shortages in some regions. Reduced hospital visits and postponed routine check-ups during lockdowns affected diabetes diagnosis and treatment initiation. However, the pandemic highlighted the vulnerability of diabetic patients to severe COVID-19 outcomes, prompting increased awareness and prioritization of diabetes management.

The oral anti-diabetic drugs segment is expected to be the largest during the forecast period

The oral anti-diabetic drugs segment is expected to account for the largest market share during the forecast period due to their convenience and widespread use. These medications, including biguanides and DPP-4 inhibitors, offer effective glycemic control and ease of administration, driving their popularity among patients. Advancements in drug formulations and combination therapies further enhance treatment efficacy and reduce side effects. Increased adoption in regions with high diabetes prevalence, coupled with growing awareness campaigns, contributes to the segment's sustained growth.

The biosimilar insulins segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biosimilar insulins segment is predicted to witness the highest growth rate driven by increasing adoption of cost-effective alternatives to branded insulin products. Biosimilar insulins offer comparable safety and efficacy, making them an attractive option for healthcare providers aiming to reduce treatment costs. Regulatory approvals and market entry of new biosimilars have accelerated growth in this market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to high prevalence of diabetes and increasing healthcare investments. Countries such as China, India, and Japan dominate the region due to their large diabetic populations and expanding access to healthcare services. Government initiatives aimed at improving diabetes management and awareness campaigns further drive market growth. The region's strong pharmaceutical manufacturing capabilities and focus on affordable treatments ensure sustained market leadership.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by significant advancements in diabetes treatment technologies and research. The presence of leading pharmaceutical companies and robust healthcare infrastructure supports innovation in drug development. Rising prevalence of diabetes due to lifestyle changes enhances demand for effective and accessible medications. Additionally favourable reimbursement policies and increased adoption of biosimilar insulins contribute to market growth.

Key players in the market

Some of the key players in Diabetes Drugs Market include Abbott, Adocia, Amgen, AstraZeneca, Bayer AG, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Merck & Co., Mylan, Novartis, Novo Nordisk, Peptron, Pfizer, Sanofi, Sun Pharmaceuticals and Takeda Pharmaceuticals.

Key Developments:

In April 2025, Novo Nordisk announced a $1.09 billion investment to expand its manufacturing facility in Minas Gerais, Brazil. This expansion aims to significantly increase the production capacity of injectable medications for obesity, diabetes, and other chronic diseases, with operations expected to commence by 2028.

In March 2025, Biocon entered into an exclusive licensing and supply agreement with Brazil-based Biomm SA for the commercialization of Semaglutide, a drug used to improve glycemic control in adults with type-2 diabetes.

In February 2025, Dr. Reddy's Laboratories received approval from the Central Drug Standard Control Organisation (CDSCO) to conduct a Phase III clinical trial evaluating the efficacy, safety, and tolerability of its oral Semaglutide tablets compared to RYBELSUS (Semaglutide) tablets in adult patients with inadequately controlled type-2 diabetes mellitus.

Products Covered:

  • Insulin
  • Oral Anti-Diabetic Drugs
  • Injectable Non-Insulin Drugs
  • Combination Drugs

Diabetes Types Covered:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes / Impaired Glucose Tolerance

Formulations Covered:

  • Vials
  • Pens
  • Pumps
  • Biosimilar Insulins
  • Other Formulations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetes Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Insulin
    • 5.2.1 Rapid-Acting Insulin
      • 5.2.1.1 Insulin Aspart
      • 5.2.1.2 Insulin Lispro
      • 5.2.1.3 Insulin Glulisine
    • 5.2.2 Long-Acting Insulin
      • 5.2.2.1 Insulin Detemir
      • 5.2.2.2 Insulin Degludec
    • 5.2.3 Short-Acting Insulin
      • 5.2.3.1 Humulin R
      • 5.2.3.2 Novolin R
    • 5.2.4 Intermediate-Acting Insulin
  • 5.3 Oral Anti-Diabetic Drugs
    • 5.3.1 Biguanides
    • 5.3.2 Sulfonylureas
    • 5.3.3 Thiazolidinediones (TZDs)
    • 5.3.4 DPP-4 Inhibitors
    • 5.3.5 SGLT-2 Inhibitors
    • 5.3.6 Alpha-glucosidase Inhibitors
  • 5.4 Injectable Non-Insulin Drugs
    • 5.4.1 GLP-1 Receptor Agonists
    • 5.4.2 Amylin Analogs
  • 5.5 Combination Drugs

6 Global Diabetes Drugs Market, By Diabetes Type

  • 6.1 Introduction
  • 6.2 Type 1 Diabetes
  • 6.3 Type 2 Diabetes
  • 6.4 Gestational Diabetes
  • 6.5 Prediabetes / Impaired Glucose Tolerance

7 Global Diabetes Drugs Market, By Formulation

  • 7.1 Introduction
  • 7.2 Vials
  • 7.3 Pens
  • 7.4 Pumps
  • 7.5 Biosimilar Insulins
  • 7.6 Other Formulations

8 Global Diabetes Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Diabetes Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Adocia
  • 11.3 Amgen
  • 11.4 AstraZeneca
  • 11.5 Bayers AG
  • 11.6 Biocon
  • 11.7 Boehringer Ingelheim
  • 11.8 Bristol Myers Squibb
  • 11.9 Dr. Reddy's Laboratories
  • 11.10 Eli Lilly
  • 11.11 Johnson & Johnson
  • 11.12 Merck & Co.
  • 11.13 Mylan
  • 11.14 Novartis
  • 11.15 Novo Nordisk
  • 11.16 Peptron
  • 11.17 Pfizer
  • 11.18 Sanofi
  • 11.19 Sun Pharmaceuticals
  • 11.20 Takeda Pharmaceuticals

List of Tables

  • Table 1 Global Diabetes Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Diabetes Drugs Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Diabetes Drugs Market Outlook, By Insulin (2024-2032) ($MN)
  • Table 4 Global Diabetes Drugs Market Outlook, By Rapid-Acting Insulin (2024-2032) ($MN)
  • Table 5 Global Diabetes Drugs Market Outlook, By Insulin Aspart (2024-2032) ($MN)
  • Table 6 Global Diabetes Drugs Market Outlook, By Insulin Lispro (2024-2032) ($MN)
  • Table 7 Global Diabetes Drugs Market Outlook, By Insulin Glulisine (2024-2032) ($MN)
  • Table 8 Global Diabetes Drugs Market Outlook, By Long-Acting Insulin (2024-2032) ($MN)
  • Table 9 Global Diabetes Drugs Market Outlook, By Insulin Detemir (2024-2032) ($MN)
  • Table 10 Global Diabetes Drugs Market Outlook, By Insulin Degludec (2024-2032) ($MN)
  • Table 11 Global Diabetes Drugs Market Outlook, By Short-Acting Insulin (2024-2032) ($MN)
  • Table 12 Global Diabetes Drugs Market Outlook, By Humulin R (2024-2032) ($MN)
  • Table 13 Global Diabetes Drugs Market Outlook, By Novolin R (2024-2032) ($MN)
  • Table 14 Global Diabetes Drugs Market Outlook, By Intermediate-Acting Insulin (2024-2032) ($MN)
  • Table 15 Global Diabetes Drugs Market Outlook, By Oral Anti-Diabetic Drugs (2024-2032) ($MN)
  • Table 16 Global Diabetes Drugs Market Outlook, By Biguanides (2024-2032) ($MN)
  • Table 17 Global Diabetes Drugs Market Outlook, By Sulfonylureas (2024-2032) ($MN)
  • Table 18 Global Diabetes Drugs Market Outlook, By Thiazolidinediones (TZDs) (2024-2032) ($MN)
  • Table 19 Global Diabetes Drugs Market Outlook, By DPP-4 Inhibitors (2024-2032) ($MN)
  • Table 20 Global Diabetes Drugs Market Outlook, By SGLT-2 Inhibitors (2024-2032) ($MN)
  • Table 21 Global Diabetes Drugs Market Outlook, By Alpha-glucosidase Inhibitors (2024-2032) ($MN)
  • Table 22 Global Diabetes Drugs Market Outlook, By Injectable Non-Insulin Drugs (2024-2032) ($MN)
  • Table 23 Global Diabetes Drugs Market Outlook, By GLP-1 Receptor Agonists (2024-2032) ($MN)
  • Table 24 Global Diabetes Drugs Market Outlook, By Amylin Analogs (2024-2032) ($MN)
  • Table 25 Global Diabetes Drugs Market Outlook, By Combination Drugs (2024-2032) ($MN)
  • Table 26 Global Diabetes Drugs Market Outlook, By Diabetes Type (2024-2032) ($MN)
  • Table 27 Global Diabetes Drugs Market Outlook, By Type 1 Diabetes (2024-2032) ($MN)
  • Table 28 Global Diabetes Drugs Market Outlook, By Type 2 Diabetes (2024-2032) ($MN)
  • Table 29 Global Diabetes Drugs Market Outlook, By Gestational Diabetes (2024-2032) ($MN)
  • Table 30 Global Diabetes Drugs Market Outlook, By Prediabetes / Impaired Glucose Tolerance (2024-2032) ($MN)
  • Table 31 Global Diabetes Drugs Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 32 Global Diabetes Drugs Market Outlook, By Vials (2024-2032) ($MN)
  • Table 33 Global Diabetes Drugs Market Outlook, By Pens (2024-2032) ($MN)
  • Table 34 Global Diabetes Drugs Market Outlook, By Pumps (2024-2032) ($MN)
  • Table 35 Global Diabetes Drugs Market Outlook, By Biosimilar Insulins (2024-2032) ($MN)
  • Table 36 Global Diabetes Drugs Market Outlook, By Other Formulations (2024-2032) ($MN)
  • Table 37 Global Diabetes Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 38 Global Diabetes Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 39 Global Diabetes Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 40 Global Diabetes Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 41 Global Diabetes Drugs Market Outlook, By Other Distribution Channels (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.